USPTO Patent Grants - Organic Chemistry (C07D)

N-Acylhydrazonic Compounds Treat Amyloid Diseases, Patent Grant

USPTO granted patent US12600701B2 to Faculdades Católicas for N-acylhydrazonic compounds structurally derived from 1-methyl-1H-imidazole-2-carboxaldehyde for preventing and treating amyloid degenerative aggregopathies including Alzheimer's disease, Parkinson's disease, and type 2 diabetes, as well as non-amyloid conditions such as cataracts. The patent covers four specific compounds and pharmaceutical compositions containing them.

Roche Diagnostics Imidazolium Reagent Mass Spectrometry Patent Grant

The USPTO granted Patent US12600700B2 to Roche Diagnostics Operations, Inc. covering imidazolium compounds and methods for mass spectrometric determination of analyte molecules. The patent, applied for in November 2022 under application number 17991282, was granted with 14 claims. The invention relates to compounds suitable for use in mass spectrometry and associated analytical methods.

Thiosemicarbazates and Uses Thereof - US12600699B2

The USPTO granted Patent US12600699B2 to The Feinstein Institutes for Medical Research covering thiosemicarbazates, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides. The patent also protects a chemoselective functionalization protocol using Mitsunobu reaction for site-specific alkylation. Methods for preparing and using these compounds in drug discovery, diagnosis, inhibition, prevention and treatment of diseases are included in the 17 granted claims.

Kinase Inhibitors Patent - VIDYA Therapeutics, Inc.

USPTO granted Patent US12600698B2 to VIDYA Therapeutics, Inc. on April 14, 2026. The patent covers Bruton tyrosine kinase (BTK) inhibitors designed to penetrate the central nervous system, including pharmaceutical compositions and methods of treatment. The patent includes 21 claims with an August 2022 filing date.

Compositions and Methods for Removal of NMP Degradation Products from NMP Purification Systems

USPTO granted patent US12600697B2 to Refined Technologies, Inc. covering methods for cleaning N-methyl-2-pyrrolidone (NMP) purification and recovery systems. The patent claims compositions and methods using a cleaning solution containing a solvent with a primary amine and hydroxyl group, injected into reflux drums and reboilers, circulated through separation towers to solubilize foulants, then drained. The patent was filed May 25, 2022, and contains 15 claims under CPC classifications C07D 207/267 and C07D 201/16.

Markers, Conjugates, Compositions and Methods for Hypoxia Imaging, Mapping, and Therapy

USPTO granted patent US12600742B2 to WWIKY Biosciences Inc. on April 14, 2026. The patent covers markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy using bio-reductively activated compounds with click chemistry. Inventors include Piyush Kumar, Hassan Elsaidi, Leonard Irving Wiebe, and Michael Weinfeld. The patent includes 5 claims.

Japan Science and Technology Agency V-ATPase Inhibitor Patent

USPTO granted patent US12599588B2 to Japan Science and Technology Agency for an inhibitor of Na+-translocating V-ATPase activity. The compound serves as an antibacterial agent and medicine with applications in antibacterial and screening methods. The patent application was filed January 15, 2020, contains 12 claims, and covers compounds with specific structural features including hydroxy, alkoxy, and amino substituents on phenyl groups.

Chlorinated Tetralin Compounds and Pharmaceutical Compositions

USPTO granted patent US12599587B2 to Springworks Therapeutics, Inc. on April 14, 2026. The patent covers chlorinated tetralin compounds and pharmaceutical compositions, classified under C07D 233/88 and A61K 31/417. The application (No. 18490993) was filed on October 20, 2023, and the granted patent contains 19 claims.

Pyrrole Compounds Patent - Aligos Therapeutics - US12599582B2

USPTO granted Patent US12599582B2 to Aligos Therapeutics covering pyrrole compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions, and methods of treating diseases and conditions. The patent names inventors Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, and Vladimir Serebryany. The application was filed August 22, 2023, with 2 claims granted.

Bayer Aktiengesellschaft Substituted Isophthalic Acid Diamides Herbicide Patent, US12599136B2

The USPTO granted Patent US12599136B2 to Bayer Aktiengesellschaft covering substituted isophthalic acid diamides of general formula (I) for use as herbicides. The patent includes 15 claims covering compounds where X and Y are hydrogen, alkyl, or halogen radicals, and Z1 and Z2 are alkyl, cycloalkyl, or phenyl radicals with a heterocyclic Q ring. The patent was filed April 1, 2021, under Application No. 17995662.

Inhibitors of SARM1 for Axonal Degeneration Treatment

USPTO granted patent US12595252B2 to DISARM Therapeutics, Inc. on April 7, 2026, covering SARM1 inhibitor compounds and methods for treating axonal degeneration. The patent includes 4 claims and covers specific chemical compositions useful in neurological disease treatment.

PRMT5 inhibitors for cancer treatment

USPTO granted patent US12595248B2 to Merck Sharp & Dohme LLC covering PRMT5 inhibitor compounds of Formula I and their use in treating cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent includes 32 claims covering the compound compositions, methods of making, pharmaceutical formulations, and treatment methods.

Substituted pyrazolo piperidine carboxylic acids

USPTO granted patent US12595247B2 to Bayer Aktiengesellschaft covering substituted pyrazolo piperidine carboxylic acids, their salts, and processes for preparation. The patent includes 6 claims and lists 18 inventors. The compounds are directed toward cardiovascular and cardiac diseases, including heart failure with reduced, mid-range, and preserved ejection fraction.

MET Kinase Inhibitor Patent US12595245B2 Granted

The USPTO granted patent US12595245B2 to Celyn Therapeutics, Inc. covering MET receptor tyrosine kinase inhibitor compounds, pharmaceutical compositions, and methods of use for treating disease. The patent contains 18 claims and is classified under CPC codes C07D 401/12, C07D 215/22, C07D 405/14, and C07D 471/04. This grant establishes enforceable intellectual property rights for the disclosed MET kinase inhibitors.

Heterocyclic GLP-1 agonists

USPTO granted patent US12595264B2 to Gasherbrum Bio, Inc. on April 7, 2026, covering heterocyclic GLP-1 receptor agonists of Formula (I), including pharmaceutical salts, solvates, and compositions. The patent names six inventors and contains 24 claims, with CPC classifications spanning heterocyclic chemistry (C07D 487/04), phosphorus compounds (C07F 9/6561), and pharmaceutical formulations (A61K 31/4985, A61K 38/26).

PRMT5 inhibitors for cancer, sickle cell, and HPFH treatment

USPTO granted patent US12595262B2 to Merck Sharp & Dohme LLC for PRMT5 inhibitor compounds and methods of treatment for cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent covers 14 claims including compounds A through D and their pharmaceutical salts, esters, and prodrugs.

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims

Acid anhydride compound, polyamideimide resin and film

USPTO granted Patent US12595268B2 to Korea Advanced Institute of Science and Technology (KAIST) for a novel acid anhydride compound and polyamideimide resin and film utilizing the same. The invention provides high thermal resistance, low coefficient of thermal expansion, and colorless transparency properties. The patent contains 11 claims and was filed under Application No. 18517326.

Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07

Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07

Benzo nitrogen-containing heteroaromatic ring derivative for complement factor B treatment

The USPTO granted patent US12595270B2 to Xizang Haisco Pharmaceutical Co., Ltd. covering a benzo nitrogen-containing heteroaromatic ring derivative (general formula I) and its use in treating diseases associated with complement factor B activity or expression. The patent includes 8 claims encompassing the compound, stereoisomers, deuterates, solvates, prodrugs, metabolites, and pharmaceutically acceptable salts or co-crystals.

Amide EZH2 Inhibitor Patent - Preparation Method and Medical Applications

The USPTO granted patent US12595267B2 to Shanghai Synergy Pharmaceutical Sciences Co., Ltd. covering an amide small molecule compound that inhibits EZH2 (Zeste gene enhancer homolog 2). The patent protects methods for preparing the compound and its use in treating EZH2-mediated diseases including tumors, myeloproliferative diseases, and autoimmune diseases. The patent contains 11 claims and names 19 inventors.

Bioactive benzocycloheptene analogues as PI3K/MK2 inhibitors

USPTO granted Patent US12595234B2 to the Council of Scientific & Industrial Research for bioactive benzocycloheptene analogues that inhibit PI3K and MK2. The patent covers compounds for treating type 2 diabetes, inflammatory conditions, epilepsy, cancer, and CNS disorders. The patent contains 10 claims.

Mesembrine Crystalline Salt Patent Grant

USPTO granted Patent US12595231B2 to Kanna Health Ltd covering novel crystalline salt forms of mesembrine, specifically mesembrine besylate salt. The patent, filed under Application No. 18614136 with 18 claims, covers the chemical compound (C17H23NO3) and its use as a medicament.

MDM2 Inhibitor Patent Granted to Bahcesehir University

The USPTO granted Bahcesehir University Patent No. US12595232B2 for a novel Mouse Double Minute 2 (MDM2) inhibitor compound. The patent covers formula (I) compounds or pharmaceutically acceptable derivatives for inhibiting MDM2 activity. Application No. 17904403 was filed February 16, 2021, and the patent contains 2 claims.

STAT3 inhibitor prodrug patent compositions

USPTO granted patent US12594265B2 to Ohio State Innovation Foundation for prodrug compositions inhibiting STAT3 (including STAT3). The patent covers pharmaceutical compositions for treating inflammatory disorders (including multiple sclerosis) and cancers of uncontrolled cellular proliferation. Inventors: Yuhong Yang, Chenglong Li, Michael Racke. Application No. 17821286, 19 claims.

2,6-dioxo-3,6-dihydropyrimidine compound, bactericide, nematicide, and antifungal agent

USPTO granted patent US12593845B2 to Nippon Soda Co., Ltd. on April 7, 2026, covering a 2,6-dioxo-3,6-dihydropyrimidine compound for use as an agricultural and horticultural bactericide, nematicide, and medical/veterinary antifungal agent. The patent contains 4 claims and names 9 inventors including Takaaki Teranishi and Hajime Shimomura.

Thiosemicarbazates and Uses Thereof

The USPTO granted patent US12595233B2 to The Feinstein Institutes for Medical Research on April 7, 2026. The patent covers thiosemicarbazates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides, along with methods for their synthesis and applications in drug discovery, diagnosis, inhibition, prevention, and treatment of diseases. The patent names Yousef Al-Abed and Ahmad Altiti as inventors.

Spiromacrocyclic orexin 2 receptor agonists

USPTO granted Patent No. US12590106B2 to H. Lundbeck A/S for novel spiromacrocyclic orexin 2 receptor agonists used in CNS treatments. The patent, covering 18 claims, names 11 inventors including Karsten Juhl, Wanwan Yu, and Thomas Leegaard Andersen, with application originally filed as EP19195185.

Corrosion inhibitor formulations with pyridinium and hydroxy substituents

The USPTO granted patent US12590256B2 to Saudi Arabian Oil Company on March 31, 2026, covering corrosion inhibitor formulations containing compounds with both pyridinium and hydroxy substituents. The patent includes 6 claims and covers methods of making the compounds and processes for inhibiting corrosion on metallic surfaces. Inventors include Muhammad Imran Ul-haq, Nayef M. Alanazi, Turki M. Al Abeedi, Abdullah Al-Malki, and Faisal M. Al-Mutahhar.

KRas G12C inhibitors for cancer treatment

The USPTO granted patent US12590105B2 to Eli Lilly and Company on March 31, 2026, covering 24 claims for KRas G12C inhibitors and their use in treating cancer. The patent, with application number 18255713 filed on November 24, 2021, protects specific compound formulations and methods of treatment. This grant provides Eli Lilly with enforceable intellectual property rights in the United States.

Bristol-Myers Squibb pyrrolo TLR9 inhibitors for fibrosis, 31st Mar

Bristol-Myers Squibb pyrrolo TLR9 inhibitors for fibrosis, 31st Mar

Substituted Entecavir Monophosphate Alaninamide Phenolic Esters for Hepatitis B

The USPTO granted Patent No. US12590097B2 to Beijing Junke Huayuan Med Tech Co., Ltd. on March 31, 2026, covering entecavir monophosphate alaninamide phenolic ester derivatives for hepatitis B treatment. The patent grants exclusive rights to the pharmaceutical compound for resisting hepatitis B virus. This is a routine patent grant notification.

Spiroindoline pyrrolopyrrole triones NRF2-β-TrCP inhibitors for fatty liver treatment

USPTO granted Patent US12590100B2 to researchers from Universidad Autonoma de Madrid and CSIC for spiroindoline pyrrolopyrrole trione compounds that inhibit the NRF2-β-TrCP interaction for treating fatty liver disease. The patent covers 3 claims and relates to therapeutic applications for chronic inflammation and oxidative stress-related liver conditions.

Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection

USPTO granted Patent US12590099B2 to Merck Sharp & Dohme LLC covering HDAC (histone deacetylase) inhibitors useful for treating or preventing HIV infection. The patent protects compounds of Formula I, pharmaceutical compositions thereof, and methods of treatment. Four claims were granted. The patent application was filed on November 4, 2019.

Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same

The USPTO granted Patent US12590098B2 to Axceso Biopharma Co., Ltd. on March 31, 2026, covering a pyrimido pyrimidinone compound that inhibits PD-L1 expression for cancer treatment. The patent includes 9 claims and names 8 inventors including Young Jun Park and Sung Jun Park.

Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists for cancer treatment

USPTO granted Patent US12590096B2 to BeOne Medicines GmbH for an imidazo[2,1-f][1,2,4]triazin-4-amine derivative as a TLR8 agonist for treating cancers. The patent contains 18 claims and was filed on July 31, 2020 (Application No. 17632027). The compound is classified under 12 CPC codes spanning antineoplastic, antiviral, and anti-inflammatory applications.

Crystalline Forms of Orally Available Selective KIT and PDGFR Kinase Inhibitor

USPTO granted patent US12590095B2 to Sandoz AG on March 31, 2026, covering crystalline forms of avapritinib, a KIT and PDGFR kinase inhibitor. The patent (CPC C07D 487/04) protects polymorphs and hydrates of the compound for treating gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM). Inventors include Verena Adamer, Andrea Thaler, and Erwin Schreiner.

Compounds for the treatment of neurodegenerative and metabolic disorders

USPTO granted Patent US12590094B2 to University of Florida Research Foundation for heterocyclic compounds targeting neurodegenerative diseases linked to protein misfolding, including Alzheimer's, Parkinson's, ALS, and prion diseases, as well as metabolic disorders. The patent covers 8 lead compound series demonstrating NAD-restoring properties and therapeutic efficacy in cellular and animal models.

Indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound and use thereof

USPTO granted patent US12590093B2 to the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, covering an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound for treating cardiovascular and cerebrovascular diseases. The patent lists 13 inventors and contains 4 claims, with applications including increasing expression of AMPK, ABCA1, and SR-BI, and inhibiting NLRP3, IL-1β, NF-κB, and MAPKs.

Antiviral agents and uses thereof

The USPTO granted Patent US12590092B2 to Griffith University for antiviral compounds of Formula (I) and pharmaceutical compositions for treating viral infections. The patent, with 21 allowed claims, names Mark Von Itzstein, Ibrahim El-Deeb, Patrice Guillon, and Larissa Heilig as inventors. Filing date was January 28, 2022.

Foghorn Therapeutics Patent for Heterocyclic Compounds Treating BAF Disorders

The USPTO granted patent US12590079B2 to Foghorn Therapeutics Inc. on March 31, 2026, covering heterocyclic compounds useful for treating BAF complex-related disorders. The patent names inventors Sabine K. Ruppel, Zhaoxia Yang, and Jason T. Lowe, with claims encompassing 20 compound variations classified under CPC codes C07D 401/14, C07D 471/04, C07D 471/10, and C07D 487/04.

Fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment

USPTO granted Patent US12590081B2 to Jiangsu Hengrui Pharmaceuticals Co., Ltd. for fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment. The patent covers 21 claims for compounds, preparation methods, and pharmaceutical compositions containing the derivatives.

Heterocyclic compound for organic electroluminescent elements

USPTO granted Patent US12590076B2 to Idemitsu Kosan Co., Ltd. for a heterocyclic compound represented by formula (1) used in organic electroluminescent elements. The patent, filed on May 10, 2019 (Application No. 17053630), contains 26 claims and covers compounds classified under CPC codes including C07D 307/91 and H01L 51/0052.

Pyrimidine-Nitrogen Bicyclic IRAK-4 Inhibitor Compound Patent

USPTO granted patent US12590090B2 to Asahi Kasei Pharma Corporation covering pyrimidine-and nitrogen-containing bicyclic compounds with IRAK-4 inhibitory activity. The patent, with 35 claims filed on September 30, 2020, protects compounds useful for prophylactic and therapeutic treatment of diseases relating to IRAK-4 inhibition.

Gilead Sciences patent for toll-like receptor modulator compounds

USPTO granted Patent US12590089B2 to Gilead Sciences covering methods for preparing toll-like receptor modulator compounds. The patent, naming 12 inventors including Andrea Ambrosi and Pavel R. Badalov, contains 7 claims relating to (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or salts thereof. Application No. 17673141 was filed February 16, 2022.

JAK Inhibitor Compound and Pharmaceutical Composition Patent

USPTO granted Patent US12590088B2 to Korea Pharma Co., Ltd. on March 31, 2026, covering a JAK inhibitor compound and pharmaceutical composition. The patent claims 4 items related to compounds of Formula I and their use in treating inflammatory, autoimmune, myeloproliferative diseases, and human cancers by regulating JAK kinase signal transduction.

GPR139 Antagonist Patent for Depression and Neurological Disorders

USPTO granted Takeda Pharmaceutical Company Limited Patent US12590086B2 for GPR139 antagonist compounds (3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives) used in methods of treating depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and ADHD. The patent contains 27 claims and includes tablet formulations.

Oxadiazole HDAC6 inhibitors and uses thereof

The USPTO granted Patent US12590084B2 to Eikonizo Therapeutics, Inc. covering oxadiazole compounds that selectively inhibit HDAC6, a protein linked to cancer and neurological disorders including Alzheimer's disease. The patent includes 20 claims and covers pharmaceutical compositions and methods of treating HDAC6-related diseases. Inventors are Florence Fevrier Wagner and Thomas Edward Richardson.

SPNS2 inhibitors patent granted to University of Virginia

USPTO granted patent US12590083B2 to the University of Virginia Patent Foundation covering SPNS2 (spinster homolog 2) inhibitor compounds and their pharmaceutical compositions for therapeutic use. The patent, with 2 claims, protects Formula I compounds and methods of treatment using these inhibitors.

Fused tricyclic drug patent granted, Mar 31

Fused tricyclic drug patent granted, Mar 31